ANS is committed to advancing, fostering, and promoting the development and application of nuclear sciences and technologies to benefit society.
Explore the many uses for nuclear science and its impact on energy, the environment, healthcare, food, and more.
Explore membership for yourself or for your organization.
Conference Spotlight
2026 ANS Annual Conference
May 31–June 3, 2026
Denver, CO|Sheraton Denver
Latest Magazine Issues
Mar 2026
Jan 2026
Latest Journal Issues
Nuclear Science and Engineering
April 2026
Nuclear Technology
February 2026
Fusion Science and Technology
Latest News
RIC session focuses on interagency collaboration
Attendees at last week’s 2026 Regulatory Information Conference, hosted by the Nuclear Regulatory Commission, saw extensive discussion of new reactor technologies, uprates, fusion, multiunit deployments, supply chain, and much more.
With the industry in a state of rapid evolution, there was much to discuss. Connected to all these topics was one central theme: the ongoing changes at the NRC. With massively shortened timelines, the ADVANCE Act and Executive Order 14300, and new interagency collaboration and authorization pathways in mind, speakers spent much of the RIC exploring what the road ahead looks like for the NRC.
Jonas D. Fontenot, Phillip Taddei, Yuanshui Zheng, Dragan Mirkovic, Wayne D. Newhauser
Nuclear Technology | Volume 168 | Number 1 | October 2009 | Pages 173-177
Dose/Dose Rate | Special Issue on the 11th International Conference on Radiation Shielding and the 15th Topical Meeting of the Radiation Protection and Shielding Division (Part 1) / Radiation Protection | doi.org/10.13182/NT09-A9121
Articles are hosted by Taylor and Francis Online.
The purpose of this study was to evaluate the suitability of the quantity ambient dose equivalent H*(10) as a conservative estimate of effective dose E for estimating stray radiation exposures to patients receiving passively scattered proton radiotherapy for cancer of the prostate. H*(10), which is determined from fluence free-in-air, is potentially useful because it is simpler to measure or calculate because it avoids the complexities associated with phantoms or patient anatomy. However, the suitability of H*(10) as a surrogate for E has not been demonstrated for exposures to high-energy neutrons emanating from radiation treatments with proton beams. The suitability was tested by calculating H*(10) and E for a proton treatment using a Monte Carlo model of a double-scattering treatment machine and a computerized anthropomorphic phantom. The calculated E for the simulated treatment was 5.5 mSv/Gy, while the calculated H*(10) at the isocenter was 10 mSv/Gy. A sensitivity analysis revealed that H*(10) conservatively estimated E for the interval of treatment parameters common in proton therapy for prostate cancer. However, sensitivity analysis of a broader interval of parameters suggested that H*(10) may underestimate E for treatments of other sites, particularly those that require large field sizes. Simulations revealed that while E was predominated by neutrons generated in the nozzle, neutrons produced in the patient contributed up to 40% to dose equivalent in near-field organs.